The latest price target for Solid Biosciences (NASDAQ:SLDB) was reported by Barclays on August 14, 2024. The analyst firm set a price target for $15.00 expecting SLDB to rise to within 12 months (a possible 87.03% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for Solid Biosciences (NASDAQ:SLDB) was provided by Barclays, and Solid Biosciences maintained their overweight rating.

The last upgrade for Solid Biosciences Inc happened on July 15, 2024 when JP Morgan raised their price target to $15. JP Morgan previously had a neutral for Solid Biosciences Inc.

The last downgrade for Solid Biosciences Inc happened on October 17, 2022 when SVB Leerink changed their price target from $12 to $1 for Solid Biosciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Solid Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Solid Biosciences was filed on August 14, 2024 so you should expect the next rating to be made available sometime around August 14, 2025.

While ratings are subjective and will change, the latest Solid Biosciences (SLDB) rating was a maintained with a price target of $18.00 to $15.00. The current price Solid Biosciences (SLDB) is trading at is $8.02, which is out of the analyst’s predicted range.